Want to see ZNTL full AI Analyst Report?
Total Valuation
Zentalis Pharmaceuticals has a market cap or net worth of $367.33M. The enterprise value is $209.01.
Market Cap$367.33M
Enterprise Value$209.01
Share Statistics
Zentalis Pharmaceuticals has 94,671,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,671,910
Owned by Insiders27.51%
Owned by Institutions19.34%
Financial Efficiency
Zentalis Pharmaceuticals’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -59.63%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-59.63%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-1.29M
Employee Count106
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zentalis Pharmaceuticals is ―. Zentalis Pharmaceuticals’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio0.45
Price to Fair Value0.45
Price to FCF-0.77
Price to Operating Cash Flow-1.70
PEG Ratio0.04
Income Statement
In the last 12 months, Zentalis Pharmaceuticals had revenue of 0.00 and earned -137.06M in profits. Earnings per share was -1.91.
Revenue0.00
Gross Profit0.00
Operating Income-152.81M
Pretax Income-136.62M
Net Income-137.06M
EBITDA-144.27M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -161.05M and capital expenditures -68.00K, giving a free cash flow of -161.12M billion.
Operating Cash Flow-161.05M
Free Cash Flow-161.12M
Free Cash Flow per Share-1.70
Dividends & Yields
Zentalis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.36
52-Week Price Change113.74%
50-Day Moving Average4.34
200-Day Moving Average3.17
Relative Strength Index (RSI)43.02
Average Volume (3m)716.92K
Important Dates
Zentalis Pharmaceuticals upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Zentalis Pharmaceuticals as a current ratio of 6.93, with Debt / Equity ratio of 26.24%
Current Ratio6.93
Quick Ratio6.93
Debt to Market Cap0.04
Net Debt to EBITDA-0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Zentalis Pharmaceuticals has paid 442.00K in taxes.
Income Tax442.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Zentalis Pharmaceuticals EV to EBITDA ratio is -0.70, with an EV/FCF ratio of -0.80.
EV to Sales0.00
EV to EBITDA-0.70
EV to Free Cash Flow-0.80
EV to Operating Cash Flow-0.80
Balance Sheet
Zentalis Pharmaceuticals has $174.61M in cash and marketable securities with $37.69M in debt, giving a net cash position of $136.92M billion.
Cash & Marketable Securities$174.61M
Total Debt$37.69M
Net Cash$136.92M
Net Cash Per Share$1.45
Tangible Book Value Per Share$3.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Zentalis Pharmaceuticals is $8.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.83
Price Target Upside127.66% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast14.08%